Review for 10.1186/s12876-016-0530-4 (2016)

Reviewer ’s report  
 
Title: Prevalence of medication discrepancies in patients with cirrhosis: a pilot study  
 
 
Version: 0 Date: 01 Jan 2 016 
 
 
Reviewer: Sofia  Ornelas -Arroyo   
 
 
Reviewer's report:  
 
 
Dear authors regarding to your work it is a very interesting topic, very important for hepatology 
ambu latory care.   
 
1. Frequently as a cirrhotic patient is discharged from the hospital the amount of 
medications is larger then the usual prescription, and sometimes they also have to take 
some temporary medication such as antibiotics, because of that there m ight be an 
overestimation of discrepancies by using the ELMs and not an updated of the medication 
list in the outpatient hepatology clinic.  
 
2. Documenting the dosage would have been important in medication specified for cirrhosis 
complication such as propr anolol and diuretics since discrepancies in dosages from this 
medication could also be harmful.  
 
3. Figure 2 is a little bit difficult to understand perhaps some modifications to make it easier 
to understand.  
 
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Unable to assess  
 
Are the conclusions drawn adequately supporte d by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an  
additional statistical review?  
If an additional statistical review is recommended, please spe cify what aspects require further  
assessment in your comments to the editors.  
 
I am able to assess the statist ics 
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from 
an organisation that may in any way gain or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this manuscript, either now or in the  future?  
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied for patents relating to the content of the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I  declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests  
 
I agree to the open peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manus cript is accepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://cr eativecommons.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be included as confidential comments  
to the editors, which will not be published.  
 
I agree to the open peer review policy of the jo urnal